Abstract
The association between diabetes mellitus and coronary artery disease (CAD) is wellknown. Being the leading cause of death in diabetics, CAD is a target for prevention, diagnosis and treatment. In that sense, silent CAD in diabetics has long been a matter of concern, leading both to continued attempts at its diagnosis as well as to the persisting challenge of defining if screening for CAD in the diabetic population is useful and/or warranted.
The most frequent and stronger point in favor of screening rests on the assumption that early diagnosis of CAD may lead to early treatment and therefore improved outcomes. Nonetheless, screening for CAD in diabetics is a controversial issue, since studies have not yielded evidence supporting better outcomes in diabetics screened for CAD compared to nonscreened diabetics. For several reasons, current tests that detect inducible ischemia or assess atherosclerotic burden may not be able to identify those patients at increased risk. Therefore a cautious look should be taken (once more) at that question.
Keywords: Coronary artery disease, diabetes mellitus, screening, silent ischemia, myocardial perfusion scintigraphy, coronary artery computed tomography.
Current Diabetes Reviews
Title:Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Volume: 11 Issue: 2
Author(s): Andrea De Lorenzo
Affiliation:
Keywords: Coronary artery disease, diabetes mellitus, screening, silent ischemia, myocardial perfusion scintigraphy, coronary artery computed tomography.
Abstract: The association between diabetes mellitus and coronary artery disease (CAD) is wellknown. Being the leading cause of death in diabetics, CAD is a target for prevention, diagnosis and treatment. In that sense, silent CAD in diabetics has long been a matter of concern, leading both to continued attempts at its diagnosis as well as to the persisting challenge of defining if screening for CAD in the diabetic population is useful and/or warranted.
The most frequent and stronger point in favor of screening rests on the assumption that early diagnosis of CAD may lead to early treatment and therefore improved outcomes. Nonetheless, screening for CAD in diabetics is a controversial issue, since studies have not yielded evidence supporting better outcomes in diabetics screened for CAD compared to nonscreened diabetics. For several reasons, current tests that detect inducible ischemia or assess atherosclerotic burden may not be able to identify those patients at increased risk. Therefore a cautious look should be taken (once more) at that question.
Export Options
About this article
Cite this article as:
Lorenzo De Andrea, Screening for Silent Coronary Artery Disease in Diabetics- or Not?, Current Diabetes Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573399811666150108122443
DOI https://dx.doi.org/10.2174/1573399811666150108122443 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SUMOylation in Neurological Diseases
Current Molecular Medicine <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Lipid-Based Systems for Delivery of Biological Macromolecules
Recent Patents on Nanomedicine Patent Selections :
Recent Patents on Biomarkers Immunophilins are Involved in the Altered Platelet Aggregation Observed in Patients with Type 2 Diabetes Mellitus
Current Medicinal Chemistry Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Drug Delivery Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Biomedical Applications of Natural Polymers for Drug Delivery
Current Organic Chemistry Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry